Increased Kremen2 predicts worse prognosis in colon cancer
Pathology and Oncology Research · 12.04.2023 · 29
DOI: 10.3389/pore.2023.1611082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology and Oncology Research, online erschienen am 12.04.2023. Verfasst von Junxian Long und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Colorectal and Anal Surgery, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Colonic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Colon cancer (CC) is the fifth most prevalent cancer around the globe and poses a major risk to human health. Even though Kremen2 serves as a prognostic indicator in individuals with malignant tumours, its role in evaluating the prognosis of individuals with colon cancer has not been confirmed.
Methods
Here, we examined the protein expression of Kremen2 in CC tissues and paired adjacent normal tissues by immunohistochemistry (IHC), then analyzed the clinical and RNA-seq data presented in The Cancer Genome Atlas (TCGA) database to confirm the relationship between Kremen2 levels and CC. In addition, the associations between Kremen2 mRNA expression and infiltrating immune cells were examined.
Results
The study showed that the mRNA expression and protein level of Kremen2 were increased in CC tissues compared with adjacent normal tissues. According to Kaplan–Meier analysis, high Kremen2 expression in CC was linked to poor overall survival and progression-free survival. Clinical correlation analysis highlighted that a high level of Kremen2 expression was strongly linked with tumour progression, particularly lymph node metastasis. Cox regression analysis highlighted that Kremen2 was an independent prognostic indicator for CC. Bioinformatic studies highlighted that Kremen2 might be associated with the immune status in CC.
Conclusion
Increased Kremen2 could serve as a potential prognostic CC biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Colorectal and Anal Surgery, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
- Department of Breast and Thyroid Surgery, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Department of Gastroenteroanal Surgery, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
- Guangxi Clinical Research Center for Colorectal Cancer, Nanning, Guangxi, China.
Zitieren
APA
Long, J., Cong, F., Wei, Y., Liu, J., & Tang, W. (2023). Increased Kremen2 predicts worse prognosis in colon cancer. Pathology and Oncology Research, 29. https://doi.org/10.3389/pore.2023.1611082
Vancouver
Long J, Cong F, Wei Y, Liu J, Tang W. Increased Kremen2 predicts worse prognosis in colon cancer. Pathology and Oncology Research. 2023;29. doi:10.3389/pore.2023.1611082
BibTeX
@article{Long2023,
author = {Long, Junxian and Cong, Fengyun and Wei, Yousheng and Liu, Jungang and Tang, Weizhong},
title = {Increased Kremen2 predicts worse prognosis in colon cancer},
journal = {Pathology and Oncology Research},
year = {2023},
volume = {29},
doi = {10.3389/pore.2023.1611082}
}
EUVIMED